Augmented endothelial l-arginine transport ameliorates pressure-overload-induced cardiac hypertrophy

Experimental Physiology

Volumn 100, Issue 7, 2015, Pages 796-804

  Rajapakse, Niwanthi W ^a,b   Johnston, Tamara ^a   Kiriazis, Helen ^a   Chin Dusting, Jaye P ^a   Du, Xiao Jun ^a   Kaye, David M ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; ARGININE; COLLAGEN TYPE 1; MESSENGER RNA; MYOSIN HEAVY CHAIN BETA; NITRIC OXIDE;

AMINO ACID TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GENE OVEREXPRESSION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE OVERLOAD; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE WALL; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; ANIMAL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CARDIOMEGALY; DISEASE MODEL; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PRESSURE; TRANSGENIC MOUSE;

ANIMALS; ARGININE; CARDIOMEGALY; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HYPERTROPHY, LEFT VENTRICULAR; MICE, TRANSGENIC; MYOCARDIUM; MYOCYTES, CARDIAC; PRESSURE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84933513831     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/EP085250     Document Type: Article

References (40)

1. Calderone A, Thaik CM, Takahashi N, Chang DL & Colucci WS (1998). Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 101, 812-818.
2. Camelliti P, Borg TK & Kohl P (2005). Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 65, 40-51.
3. Chin-Dusting JP, Willems L & Kaye DM (2007). l-Arginine transporters in cardiovascular disease: a novel therapeutic target. Pharmacol Ther 116, 428-436.
4. Chu PY, Mariani J, Finch S, McMullen JR, Sadoshima J, Marshall T & Kaye DM (2010). Bone marrow-derived cells contribute to fibrosis in the chronically failing heart. Am J Pathol 176, 1735-1742.
5. Chu PY, Zatta A, Kiriazis H, Chin-Dusting J, Du XJ, Marshall T & Kaye DM (2011). CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess. Circ Heart Fail 4, 651-658.
6. Garcia JA & Incerpi EK (2008). Factors and mechanisms involved in left ventricular hypertrophy and the anti-hypertrophic role of nitric oxide. Arq Bras Cardiol 90, 409-416.
7. Ishigai Y, Mori T, Ikeda T, Fukuzawa A & Shibano T (1997). Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes. Am J Physiol Heart Circ Physiol 273, H2659-H2663.
8. Kaye DM, Ahlers BA, Autelitano DJ & Chin-Dusting JP (2000). In vivo and in vitro evidence for impaired arginine transport in human heart failure. Circulation 102, 2707-2712.
9. Kaye DM, Parnell MM & Ahlers BA (2002). Reduced myocardial and systemic l-arginine uptake in heart failure. Circ Res 91, 1198-1203.
10. Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA & Yanagisawa M (2001). Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol 230, 230-242.
11. Konstantinidis G, Head GA, Evans RG, Nguyen-Huu TP, Venardos K, Croft KD, Mori TA, Kaye DM & Rajapakse NW (2014). Endothelial cationic amino acid transporter-1 overexpression can prevent oxidative stress and increases in arterial pressure in response to superoxide dismutase inhibition in mice. Acta Physiol (Oxf) 210, 845-853.
12. Koshy SK, Reddy HK & Shukla HH (2003). Collagen cross-linking: new dimension to cardiac remodeling. Cardiovasc Res 57, 594-598.
13. Krayenbuehl HP, Hess OM, Monrad ES, Schneider J, Mall G & Turina M (1989). Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation 79, 744-755.
14. Leucker TM & Jones SP (2014). Endothelial dysfunction as a nexus for endothelial cell-cardiomyocyte miscommunication. Front Physiol 5, 328.
15. Levy D, Garrison RJ, Savage DD, Kannel WB & Castelli WP (1990). Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322, 1561-1566.
16. Lin Y, Wang LN, Xi YH, Li HZ, Xiao FG, Zhao YJ, Tian Y, Yang BF & Xu CQ (2008). l-Arginine inhibits isoproterenol-induced cardiac hypertrophy through nitric oxide and polyamine pathways. Basic Clin Pharmacol Toxicol 103, 124-130.
17. Lorin J, Zeller M, Guilland JC, Cottin Y, Vergely C & Rochette L (2014). Arginine and nitric oxide synthase: regulatory mechanisms and cardiovascular aspects. Mol Nutr Food Res 58, 101-116.
18. MacCarthy PA & Shah AM (2000). Impaired endothelium-dependent regulation of ventricular relaxation in pressure-overload cardiac hypertrophy. Circulation 101, 1854-1860.
19. McCormick ME, Collins C, Makarewich CA, Chen Z, Rojas M, Willis MS, Houser SR & Tzima E (2015). Platelet endothelial cell adhesion molecule-1 mediates endothelial-cardiomyocyte communication and regulates cardiac function. J Am Heart Assoc 4, e001210.
20. Maulik SK & Kumar S (2012). Oxidative stress and cardiac hypertrophy: a review. Toxicol Mech Methods 22, 359-366.
21. Mohri M, Egashira K, Tagawa T, Kuga T, Tagawa H, Harasawa Y, Shimokawa H & Takeshita A (1997). Basal release of nitric oxide is decreased in the coronary circulation in patients with heart failure. Hypertension 30, 50-56.
22. Mordi I & Tzemos N (2014). Is reversal of endothelial dysfunction still an attractive target in modern cardiology? World J Cardiol 6, 824-835.
23. Numaguchi K, Egashira K, Takemoto M, Kadokami T, Shimokawa H, Sueishi K & Takeshita A (1995). Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 26, 957-962.
24. Parnell MM, Holst DP & Kaye DM (2005). Augmentation of endothelial function following exercise training is associated with increased l-arginine transport in human heart failure. Clin Sci (Lond) 109, 523-530.
25. Rajapakse NW, Chong AL, Zhang WZ & Kaye DM (2013). Insulin-mediated activation of the L-arginine nitric oxide pathway in man, and its impairment in diabetes. PLoS ONE 8, e61840.
26. Rajapakse NW, Karim F, Straznicky NE, Fernandez S, Evans RG, Head GA & Kaye DM (2014). Augmented endothelial specific L-arginine transport prevents obesity-induced hypertension. Acta Physiol (Oxf) 212, 39-48.
27. Rajapakse NW & Mattson DL (2013). Role of cellular L-arginine uptake and nitric oxide production on renal blood flow and arterial pressure regulation. Curr Opin Nephrol Hypertens 22, 45-50.
28. Roldán V, Marín F, Gimeno JR, Ruiz-Espejo F, González J, Feliu E, García-Honrubia A, Saura D, de laMorena G, Valdés M & Vicente V (2008). Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J 156, 85-91.
29. Santos CX, Anilkumar N, Zhang M, Brewer AC & Shah AM (2011). Redox signaling in cardiac myocytes. Free Radic Biol Med 50, 777-793.
30. Shah AM (1996). Paracrine modulation of heart cell function by endothelial cells. Cardiovasc Res 31, 847-867.
31. Sheridan DJ (2000). Regression of left ventricular hypertrophy: do antihypertensive classes differ? J Hypertens Suppl 18, S21-S27.
32. Siwik DA & Colucci WS (2004). Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev 9, 43-51.
33. Siwik DA, Pagano PJ & Colucci WS (2001). Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 280, C53-60.
34. Takimoto E & Kass DA (2007). Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49, 241-248.
35. Tirziu D, Giordano FJ & Simons M (2010). Cell communications in the heart. Circulation 122, 928-937.
36. Tirziu D & Simons M (2008). Endothelium-driven myocardial growth or nitric oxide at the crossroads. Trends Cardiovasc Med 18, 299-305.
37. Xu Q, Lekgabe ED, Gao XM, Ming Z, Tregear GW, Dart AM, Bathgate RA, Samuel CS & Du XJ (2008). Endogenous relaxin does not affect chronic pressure overload-induced cardiac hypertrophy and fibrosis. Endocrinology 149, 476-482.
38. Yang CM, Kandaswamy V, Young D & Sen S (1997). Changes in collagen phenotypes during progression and regression of cardiac hypertrophy. Cardiovasc Res 36, 236-245.
39. Yang Z, Venardos K, Jones E, Morris BJ, Chin-Dusting J & Kaye DM (2007). Identification of a novel polymorphism in the 3′UTR of the l-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction. Circulation 115, 1269-1274.
40. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S & Kalluri R (2007). Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13, 952-961.